Dynamic Technology Lab Private Ltd Sells 7,790 Shares of Qiagen (NYSE:QGEN)

Dynamic Technology Lab Private Ltd cut its position in shares of Qiagen (NYSE:QGEN) by 36.8% in the third quarter, HoldingsChannel reports. The firm owned 13,372 shares of the company’s stock after selling 7,790 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Qiagen were worth $609,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in QGEN. TD Asset Management Inc bought a new stake in shares of Qiagen in the second quarter valued at about $2,103,000. Raymond James & Associates raised its holdings in shares of Qiagen by 12.7% in the 2nd quarter. Raymond James & Associates now owns 542,453 shares of the company’s stock valued at $22,289,000 after purchasing an additional 61,008 shares in the last quarter. Jennison Associates LLC lifted its position in shares of Qiagen by 5.0% in the 3rd quarter. Jennison Associates LLC now owns 1,426,392 shares of the company’s stock worth $65,001,000 after purchasing an additional 68,415 shares during the period. Barings LLC bought a new position in shares of Qiagen during the second quarter valued at approximately $12,463,000. Finally, Sei Investments Co. increased its holdings in Qiagen by 19.7% during the second quarter. Sei Investments Co. now owns 1,696,319 shares of the company’s stock valued at $69,702,000 after buying an additional 278,930 shares during the period. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Qiagen Price Performance

Shares of QGEN stock opened at $43.75 on Friday. Qiagen has a fifty-two week low of $39.03 and a fifty-two week high of $47.44. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17. The firm has a market capitalization of $9.98 billion, a price-to-earnings ratio of 112.21, a PEG ratio of 3.35 and a beta of 0.41. The stock’s 50-day simple moving average is $43.28 and its 200-day simple moving average is $43.73.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on QGEN shares. Robert W. Baird upped their target price on Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Hsbc Global Res upgraded Qiagen to a “hold” rating in a research note on Thursday, October 17th. Finally, HSBC lowered Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a research note on Thursday, October 17th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Qiagen presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.88.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.